Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.

Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mathurin Dorel, Bertram Klinger, Tommaso Mari, Joern Toedling, Eric Blanc, Clemens Messerschmidt, Michal Nadler-Holly, Matthias Ziehm, Anja Sieber, Falk Hertwig, Dieter Beule, Angelika Eggert, Johannes H Schulte, Matthias Selbach, Nils Blüthgen
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Acceso en línea:https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b10
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6c6e8d855b1e45b79a37ebbd2f6a6b10
record_format dspace
spelling oai:doaj.org-article:6c6e8d855b1e45b79a37ebbd2f6a6b102021-12-02T19:57:59ZNeuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.1553-734X1553-735810.1371/journal.pcbi.1009515https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b102021-11-01T00:00:00Zhttps://doi.org/10.1371/journal.pcbi.1009515https://doaj.org/toc/1553-734Xhttps://doaj.org/toc/1553-7358Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines. By generating quantitative perturbation data and mathematical modelling, we determined potential resistance mechanisms. We found that negative feedbacks within MAPK signalling and via the IGF receptor mediate re-activation of MAPK signalling upon treatment in resistant cell lines. By using cell-line specific models, we predict that combinations of MEK inhibitors with RAF or IGFR inhibitors can overcome resistance, and tested these predictions experimentally. In addition, phospho-proteomic profiling confirmed the cell-specific feedback effects and synergy of MEK and IGFR targeted treatment. Our study shows that a quantitative understanding of signalling and feedback mechanisms facilitated by models can help to develop and optimise therapeutic strategies. Our findings should be considered for the planning of future clinical trials introducing MEKi in the treatment of neuroblastoma.Mathurin DorelBertram KlingerTommaso MariJoern ToedlingEric BlancClemens MesserschmidtMichal Nadler-HollyMatthias ZiehmAnja SieberFalk HertwigDieter BeuleAngelika EggertJohannes H SchulteMatthias SelbachNils BlüthgenPublic Library of Science (PLoS)articleBiology (General)QH301-705.5ENPLoS Computational Biology, Vol 17, Iss 11, p e1009515 (2021)
institution DOAJ
collection DOAJ
language EN
topic Biology (General)
QH301-705.5
spellingShingle Biology (General)
QH301-705.5
Mathurin Dorel
Bertram Klinger
Tommaso Mari
Joern Toedling
Eric Blanc
Clemens Messerschmidt
Michal Nadler-Holly
Matthias Ziehm
Anja Sieber
Falk Hertwig
Dieter Beule
Angelika Eggert
Johannes H Schulte
Matthias Selbach
Nils Blüthgen
Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
description Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines. By generating quantitative perturbation data and mathematical modelling, we determined potential resistance mechanisms. We found that negative feedbacks within MAPK signalling and via the IGF receptor mediate re-activation of MAPK signalling upon treatment in resistant cell lines. By using cell-line specific models, we predict that combinations of MEK inhibitors with RAF or IGFR inhibitors can overcome resistance, and tested these predictions experimentally. In addition, phospho-proteomic profiling confirmed the cell-specific feedback effects and synergy of MEK and IGFR targeted treatment. Our study shows that a quantitative understanding of signalling and feedback mechanisms facilitated by models can help to develop and optimise therapeutic strategies. Our findings should be considered for the planning of future clinical trials introducing MEKi in the treatment of neuroblastoma.
format article
author Mathurin Dorel
Bertram Klinger
Tommaso Mari
Joern Toedling
Eric Blanc
Clemens Messerschmidt
Michal Nadler-Holly
Matthias Ziehm
Anja Sieber
Falk Hertwig
Dieter Beule
Angelika Eggert
Johannes H Schulte
Matthias Selbach
Nils Blüthgen
author_facet Mathurin Dorel
Bertram Klinger
Tommaso Mari
Joern Toedling
Eric Blanc
Clemens Messerschmidt
Michal Nadler-Holly
Matthias Ziehm
Anja Sieber
Falk Hertwig
Dieter Beule
Angelika Eggert
Johannes H Schulte
Matthias Selbach
Nils Blüthgen
author_sort Mathurin Dorel
title Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_short Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_full Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_fullStr Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_full_unstemmed Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
title_sort neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b10
work_keys_str_mv AT mathurindorel neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT bertramklinger neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT tommasomari neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT joerntoedling neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT ericblanc neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT clemensmesserschmidt neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT michalnadlerholly neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT matthiasziehm neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT anjasieber neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT falkhertwig neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT dieterbeule neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT angelikaeggert neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT johanneshschulte neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT matthiasselbach neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
AT nilsbluthgen neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance
_version_ 1718375781764169728